Asian Journal of Chemical and Pharmaceutical Research

E-ISSN: 2347-8322 | DOI: https://doi.org/10.30904/j.ajcpr.2026.5047

Benefits of Latent Artificial Intelligence Technologies for Patient Health: A Comprehensive Review

Nataraj Palaniyappan*[1], Vijayakumar Murugesan[2], Kannan Arumugam[3], M. Ravisankar[4]

[1]*Scientist, Novitium Pharma LLC, New Jersey, USA*
[2,3]*Research Scholar, School of Pharmacy, JSS Academy of Higher Education and Research, Mauritius*
[4]*Department of Pharmaceutical Chemistry, Srinivasan College of Pharmaceutical Science, Trichy*

***Corresponding E-mail:** palanatraj2020@gmail.com*

Received: 05-03- 2026 | Revised: 04-04-2026 | Accepted: 10-05- 2026 | Published: 31-05-2026

ABSTRACT

Latent artificial intelligence (AI) is transforming the way healthcare data are analyzed by helping computers in learning meaningful patterns from complex clinical information. Generally traditional AI models depend on directly visible features whereas latent AI learns hidden representations from medical images, electronic health records, molecular data, and physiological signals. This helps in identification of patterns that cannot be easily detected through traditional analytical methods. This review brings together findings from peer-reviewed studies published mainly between 2020 and 2026 to observe the clinical uses, benefits, and current limitations of major latent AI approaches like variational autoencoders, generative adversarial networks, latent diffusion models, and latent world models. The evidence shows that these models can help in improving diagnostic accuracy, particularly in medical imaging, generate realistic synthetic data while protecting patient privacy, supporting precision medicine and drug discovery through latent-space molecular design, and strengthening risk prediction using electronic health records and wearable devices. These developments have the potential to support early diagnosis, identify patients who may benefit from modified treatments, reduce the burden of routine clinical responsibilities, and help in rapid development of new therapies. At the same time, important challenges like limited model interpretability, the risk of algorithmic bias, regulatory concerns, and the need for stronger validation in diverse patient populations are still present. Overall, latent AI has the potential to become a valuable tool in modern healthcare when developed and applied with transparency, careful validation, fairness, and appropriate clinical oversight.

Keywords: latent artificial intelligence; generative models; variational autoencoders; precision medicine; clinical decision support; patient outcomes

1. Introduction

Artificial intelligence (AI) has progressed rapidly in the last few decades. It has changed from rule-based systems to deep learning models which can analyze large amounts of clinical data and identify patterns that are difficult for conventional computational methods to detect. A major step in this evolution is the development of latent AI. It not only relies upon the features that are directly observed but also learns from compact representations in complex healthcare data. These representations are generated from medical images, genomic sequences, molecular structures, physiological signals, and electronic health records (EHRs) and allow the models to recognize the underlying biological relationships and patterns of disease progression that may not be easily observed with traditional analytical approaches [1].

Generally conventional machine learning methods are trained to predict a specific output from a given input but latent AI models are designed to learn the hidden structure of the data on its own. Various approaches such as variational autoencoders (VAEs), generative adversarial networks (GANs), latent diffusion models, and the more recent latent world models achieve this by modelling the processes that give rise to the observed data [2]. Because of this, their applications extend beyond prediction. They can reconstruct missing or incomplete information, reduce noise in complex datasets, generate realistic synthetic data, simulate biological and clinical processes, and clinical representations. These capabilities have extended the role of AI in healthcare like supporting more accurate diagnosis, better-informed treatment planning, faster drug discovery, and more personalized patient care.

Latent AI is becoming increasingly important in healthcare because it has capabilities which extend beyond recognizing patterns in complex medical data. Conventional AI models are typically designed to classify diseases or predict outcomes using fixed datasets. In contrast, latent AI learns hidden representations within the data, allowing it to generate realistic, privacy-preserving synthetic patient data, address limitations caused by scarce datasets, track disease progression through latent trajectories, and identify molecular or therapeutic candidates that match an individual's biological profile [3]. These capabilities have moved beyond experimental research and are beginning to influence real-world healthcare

applications. Recent studies have shown that latent representations derived from chest radiographs and magnetic resonance imaging (MRI) can improve the early detection of cancers and neurodegenerative diseases [4,5]. Researchers have also reported that latent embeddings generated from electronic health records (EHRs) improve the prediction of conditions such as sepsis, chronic kidney disease, and cardiovascular disorders by capturing detailed clinical data which conventional models may not identify [6,7]. Latent-space modeling has also accelerated drug discovery along with diagnosis and risk prediction. By aiding the design and optimization of potential molecules, these approaches have contributed to the development of several AI-assisted therapeutic candidates that have already progressed to clinical trials [8]. Together, these advances highlight how latent AI is evolving from a promising research concept into a practical technology with the potential to improve diagnosis, treatment planning, and drug development.

This review brings together the current evidence on how latent AI technologies are improving patient care across four key areas: medical imaging and disease detection, disease prediction using electronic health records (EHRs) and physiological signals, drug discovery and personalized treatment, and remote patient monitoring like digital twin technologies. In addition to these clinical applications, the review also examines the ethical, legal, and practical issues that must be focused before latent AI can be safely and responsibly adopted in routine healthcare.

The content has been written for a broad readership, like clinicians, healthcare researchers, biomedical engineers, and artificial intelligence specialists. Wherever possible, technical concepts are explained in clear clinical language without compromising scientific accuracy. In this article, the term ‘latent AI’ refers to models that learn compact, informative representations of data rather than analyzing raw or minimally processed inputs directly. These methods include autoencoders, variational autoencoders, adversarial autoencoders, generative adversarial networks with latent representations, latent diffusion models, latent world models, and generative multi-omics frameworks. Large language models used only for writing, summarizing, or processing clinical text are outside the scope of this review. The focus is mainly on latent-variable models that support disease prediction, medical data generation, and clinical decision-making, because these technologies present distinct scientific and clinical challenges.

Previous reviews have mainly concentrated on the evolution of generative AI or the ethical questions surrounding its use [9,10]. In contrast, this review takes a patient-centered perspective by examining how latent AI contributes to better diagnosis, earlier intervention, personalized treatment strategies, and continuous health monitoring. It also contains evidence published between 2024 and 2026, suggesting the rapid transition of latent AI from an emerging research field to a technology with growing clinical importance. The evidence reviewed suggests that latent representation learning is becoming a key component of modern healthcare AI. The adoption of latent AI in clinical practice will depend on several factors, like improving model interpretability, minimizing bias across diverse patient populations, validating performance in different healthcare settings, and establishing clear regulatory frameworks to support safe implementation.

2. Materials and Methods

A structured narrative review was undertaken to examine the expanding literature on latent artificial intelligence (AI) in healthcare. This approach was selected because the available evidence discusses multiple disciplines, including computer science, radiology, pharmacology, biomedical engineering, and health policy. Before beginning the literature search, a review protocol was prepared to define the search strategy, eligibility criteria, data extraction process, and thematic framework that guided the review.

Relevant studies published between 2020 and 2026 were identified through a comprehensive literature search. The search included peer-reviewed journal articles, systematic reviews, scoping reviews, and preprints from recognized repositories such as arXiv and medRxiv. Literature was retrieved from PubMed/MEDLINE, Scopus, IEEE Xplore, ScienceDirect, Google Scholar, and arXiv. Search terms included latent AI, latent variable model, variational autoencoder, generative adversarial network, diffusion model, latent space, world model, and representation learning. These terms were combined with healthcare-related keywords such as patient outcomes, diagnosis, electronic health records, drug discovery, precision medicine, remote monitoring, and clinical decision support to capture studies relevant to patient care.

Studies were included if they described or evaluated latent-variable or generative AI methods with a direct or clearly defined application in healthcare. Only English-language publications that provided sufficient methodological detail to explain the latent representation used were taken into consideration. Articles focusing on conventional rule-based clinical decision systems or AI methods unrelated to latent or generative modeling were excluded. Opinion pieces and publications that did not present a structured evaluation of the literature were also omitted. For each eligible study, information was extracted on the type of AI model, the latent representation employed, the clinical application, characteristics of the study population or dataset, reported outcomes, and the limitations identified by the authors. There was significant variation observed with the included studies in terms of study design, evaluation methods, and stages of clinical development, ranging from early computational research to real-world healthcare applications. Because of this diversity, quantitative meta-analysis was not considered. Instead, the findings were synthesized narratively and organized into four major themes: diagnostic imaging, predictive analytics, drug discovery and personalized treatment, and remote patient monitoring with digital twin applications. The review methodology was established before the detailed evaluation of the literature to promote consistency throughout the study and minimize selection bias. This structured method provided a transparent framework for identifying, selecting, and organizing the available evidence. The findings, comparisons across studies, and overall interpretation are presented in the Results and Discussion sections.

3. Results

3.1 Diagnostic Imaging and Disease Detection

Latent-variable generative models gained much attention in medical image analysis because they show patterns that conventional AI methods cannot recognize. Rather than focusing only on image classification or prediction, these models learn compact representations from complex imaging data, including magnetic resonance imaging (MRI), computed tomography (CT), and X-ray images. These latent representations preserve important structural and disease-related information and retain the original images to be reconstructed, and the uncertainty associated with reconstruction to be estimated [1,3]. This has extended the use of latent AI in medical imaging. In addition to image classification, it is now applied to abnormality detection, synthetic image generation, and the identification of clinically important features that may not be readily visible on routine image assessment.

Among its clinical applications, abnormality detection has received the greatest attention. Latent AI models are generally trained using images from healthy individuals so that they learn the characteristics of normal anatomy. When images from new patients differ from this learned pattern, reconstruction becomes less accurate. The resulting reconstruction error can indicate the presence of an abnormal finding that deserves further clinical investigation. This approach has shown promising results in neuroimaging, where studies have demonstrated that latent-variable models can detect subtle brain changes associated with Alzheimer's disease without relying on large collections of manually labelled pathological images [19].Recent developments have also made these models easier to interpret in clinical practice. For example, β-VAE models separate different biological characteristics within the latent space, making it easier to distinguish brain atrophy related to disease from changes that occur during normal ageing on MRI. Attribute-regularized and conditional variational autoencoders further improve disease-specific image reconstruction and support clearer interpretation of imaging features associated with diseases [5].

Another important application of latent generative models is the development of synthetic medical images. Large, diverse, and privacy-protected datasets remain difficult to obtain, particularly for rare diseases. Variational autoencoders (VAEs), generative adversarial networks (GANs), and related generative methods can produce realistic synthetic images that increase the size and diversity of available datasets while protecting patient identity [4]. Better training datasets improve the reliability and generalizability of AI models, especially when a limited number of real clinical images are available.

Recent studies have also highlighted the value of latent diffusion models in medical image segmentation. These models first transform images into a compact latent representation before beginning the denoising process, reducing computational demands while maintaining high segmentation accuracy. This approach has been particularly useful for segmenting complex anatomical structures, including tumors, where defining precise boundaries remains challenging during routine clinical assessment [21,22].

3.2 Predictive Analytics from Electronic Health Records and Physiological Data

Latent representation learning has applications beyond medical imaging and is increasingly being used to analyze electronic health records (EHRs) and physiological data. Rather than processing large and complex clinical datasets in their original form, these models transform the information into compact latent representations that preserve clinically relevant patterns over time. This makes it possible to identify subtle changes in a patient's health that may not be detected through conventional analytical methods. These capabilities have supported a wide range of clinical applications, including predicting disease progression, estimating the likelihood of hospital readmission, and improving predictions of treatment response [11].

A comprehensive review published in 2024 described the rapid expansion of deep learning methods for EHR analysis, including recurrent neural networks, transformer-based models, and latent-variable models. These techniques have been investigated across several chronic diseases, particularly diabetes and cardiovascular disorders, with encouraging findings. According to the review, these models improved risk prediction and contributed to earlier clinical intervention, allowing treatment decisions to be made at a more appropriate stage of disease management [12].

The usefulness of latent AI has also been demonstrated in nephrology. Research has shown that combining latent patient representations with ensemble learning and explainable AI improves the prediction of chronic kidney disease progression. The models generate individualized risk estimates while identifying the clinical variables that contribute most to each prediction. This additional information makes the results easier to understand and supports more confident clinical decision-making [6].

Similar findings have been reported in critical care. Investigators have developed latent-state models for patients with sepsis that identify early signs of clinical deterioration while maintaining more consistent prediction performance across different patient groups. These models also indicate how individual clinical variables influence the estimated risk, making the predictions easier to interpret and increasing confidence in their use within high-risk clinical environments [7].

Another important development is the introduction of latent AI world models. Conventional prediction models generally estimate a single future outcome. In contrast, world models learn how a patient's health changes over time by combining information from medical images, electronic health records, laboratory findings, and physiological signals into a shared latent representation. Latent dynamics model then estimates how the patient's condition is likely to progress from one stage to the next [18].

An important strength of these models is their ability to support hypothetical clinical analyses. Researchers and clinicians can examine how different treatment options might influence disease progression before therapy is started. Since these models represent health as a continuously evolving process rather than

producing only a single prediction, they provide a more realistic view of disease progression. This information can support clinical decision-making and help clinicians compare treatment options before selecting the most appropriate course of care [18].

3.3 Drug Discovery and Personalized Therapeutic Design

Latent AI has become an important tool in drug discovery because it helps researchers find new drug candidates more quickly and efficiently than many traditional computational methods. Instead of treating molecules as fixed chemical structures, these models convert them into continuous latent vectors that retain important chemical and biological features. Molecules with similar therapeutic properties are grouped close together in the latent space which makes it easier to identify compounds with the greatest potential for further study [25,24]. One of the first studies in this area showed that continuous latent molecular representations could be improved using Bayesian optimization to generate new compounds with better physicochemical properties. This work formed the basis for later research on latent-space optimization in computational drug design [25]. Further developments have expanded the use of latent AI in molecular design. Latent prompt transformers and latent-space energy-based models can generate new molecules with specific biological activities while maintaining chemical validity and structural diversity [26,27]. This reduces the number of compounds that need to be synthesized and tested in the laboratory, saving both time and resources.

Latent AI is also being used in precision medicine by combining genomic, transcriptomic, proteomic, and metabolomic data into a single latent representation. Bringing these different types of biological information together helps identify disease subtypes, classify patients more accurately, and support treatment selection based on individual patient characteristics [10]. Another important use of latent AI is the design of drugs that act on more than one biological target. Instead of focusing on a single target, these models can optimize several therapeutic goals at the same time. This is especially useful for complex diseases that involve multiple biological pathways [29].

The pharmaceutical industry has increasingly adopted generative AI during the early stages of drug development. Studies have reported that AI-assisted molecular design improves lead optimization, shortens development time, and helps researchers select better drug candidates for laboratory testing [28]. Foundation models and generative AI are also being used to support clinical trial planning, patient recruitment, and biomarker discovery, extending the use of latent AI throughout the drug development process [9,15].

Latent AI has also shown promising results in antiviral drug discovery. In one study, latent generative models identified new HIV-1 reverse transcriptase inhibitors with good binding affinity and molecular stability before laboratory testing and demonstrating their potential to support the discovery of new medicines [8].

3.4 Remote Monitoring and Digital Twin Applications

The growing use of wearable devices and continuous health monitoring systems has increased the role of latent AI in personalized healthcare. Smartwatches, biosensors, electrocardiograms, continuous glucose monitors, and similar devices produce large amounts of health data every day. Latent AI processes these complex datasets and converts them into compact representations that retain important clinical information while reducing unnecessary data. This helps healthcare professionals monitor a patient's health continuously, even when the patient is outside the hospital or clinic [31].

Another important advantage of latent AI is its ability to identify small physiological changes before clear clinical symptoms develop. These models first learn the normal patterns of body function and then identify changes that may indicate the early stages of disease or worsening health. Detecting these changes at an early stage gives clinicians more time to begin treatment, may reduce avoidable hospital admissions, and supports long-term, patient-specific disease management [31].

One of the most exciting developments in this field is the digital twin. A digital twin is a virtual model of an individual patient that brings together information from wearable devices, electronic health records, medical images, laboratory test results, and genomic data. Latent world models form the basis of these systems by learning how a patient's health changes over time and predicting how the condition may progress under different treatment options [18]. Digital twins also permit clinicians to examine different treatment plans before they are used in real patients. For example, doctors can compare different medicines or treatment strategies and estimate how each one may affect disease progression. Although this technology is still being studied, it has strong potential to support personalized medicine and precision healthcare in the future [18].

Several challenges still need to be focused before digital twins become part of routine clinical practice. Many current models require additional validation in different healthcare settings. Better model interpretation, stronger privacy protection, and smooth integration with existing hospital information systems are also needed. Solving these issues will be important before latent AI-based digital twins can be widely used in everyday patient care [31,32]. The key latent AI models discussed in this review, together with their major healthcare applications and reported patient-centered benefits, are summarized in Table 1.

3.5 Patient-Reported Outcomes and Health-System-Level Impact

Latent AI is becoming an important part of clinical decision support systems (CDSSs). These systems help healthcare professionals analyze complex patient information and provide useful clinical recommendations. They combine data from medical images, laboratory tests, electronic health records, physiological measurements, and patient-reported outcomes into a shared latent representation. Bringing different types of clinical information together gives a more complete picture of a patient's condition. This supports diagnosis, treatment planning, and prediction of future health risks and reducing the amount of information clinicians must process during decision-making [13].

One important area of use is the analysis of patient-reported outcome measures (PROMs). By combining PROM data with other clinical information, latent AI models can predict

symptom progression, estimate treatment response, and assess health-related quality of life more accurately than many traditional statistical methods. A recent scoping review reported that AI-based analysis of PROMs has strong potential to improve personalized patient care. At the same time, the review noted that larger prospective studies are still needed before these models can be used routinely in clinical practice [16].

Latent AI also supports day-to-day healthcare management. It helps in organizing clinical workflows, improve the use of healthcare resources, and identify patients who need closer medical attention. These systems may help clinicians identify high-risk patients earlier, avoid unnecessary investigations, and improve the overall efficiency of healthcare services. Their successful use still depends on clear model interpretation, appropriate clinical supervision, and safe integration with existing healthcare systems [13,32].

Recent reviews have explained that good technical performance only is not enough for successful clinical use. Acceptance by healthcare professionals, compatibility with hospital information systems, appropriate regulatory oversight, and regular evaluation after implementation is also important. These factors will play a major role as latent AI becomes more widely used in routine patient care [15,32].

3.6 Image-Guided Intervention and Surgical Applications

The increasing use of latent AI in healthcare has raised several ethical and regulatory issues that need careful attention before these systems become part of routine clinical practice. Latent AI has shown promising results in areas such as medical imaging, predictive analytics, drug discovery, and remote patient monitoring. Good technical performance only is not enough for safe clinical use. Transparency, fairness, accountability, patient privacy, and appropriate clinical supervision remain essential for the responsible use of these technologies [32,33,34].

One of the main concerns is that latent AI models are often difficult to interpret. These models learn complex internal representations that are not easy for clinicians to understand. Because of this, it may be difficult to explain why a particular prediction or recommendation was made. Limited interpretability can reduce trust among healthcare professionals and slow the acceptance of latent AI in clinical practice. Developing methods that provide clear and clinically meaningful explanations is an important area of research [32]. Algorithmic bias is another major challenge. Many latent AI models are developed using data from large academic hospitals or well-resourced healthcare systems. Their performance may reduce when they are applied to different hospitals, patient populations, or demographic groups. If the training data do not represent diverse populations, the models may produce unequal results across different groups of patients. Increasing dataset diversity, performing external validation, and routinely assessing fairness can help reduce this problem [33,34].

Protecting patient privacy is equally important. Latent AI can generate realistic synthetic datasets that support research while reducing the need to share identifiable patient information. Continued research on privacy-preserving AI methods and stronger governance frameworks will be important as these technologies continue to develop [31,32]. Clear regulatory guidance and appropriate human surveillance are also needed before latent AI can be widely used in healthcare. Recent reviews highlight the importance of transparency, accountability, fairness, clinician participation, and continuous monitoring after implementation. Close collaboration among clinicians, researchers, policymakers, and regulatory agencies will help establish practical standards for the safe and equitable use of latent AI in clinical practice [32].

Future research should focus more than improving model performance. Greater attention should be given to prospective multicenter clinical studies, evaluation of patient outcomes, integration into routine healthcare practice, and the development of latent AI systems that are easier to interpret. Progress in these areas will determine how successfully latent AI improves patient care while maintaining safety, equity, and public trust [15,32,33].

Table 1. Main latent AI models, healthcare applications, and patient benefits

Latent AI model	Main healthcare application	Patient benefits
Variational Autoencoder (VAE)	Medical imaging and disease detection	Earlier and more accurate disease detection
Conditional VAE	Disease classification from medical images	Better understanding and interpretation of disease features
Generative adversarial network (GAN)	Synthetic medical image generation	More training data while protecting patient privacy
Latent diffusion model	Medical image segmentation	Faster and more accurate identification of tumors and other abnormalities
Latent-space Generative Models	Drug discovery	Faster identification of promising drug candidates
Multi-omics generative model	Personalized medicine	Treatments personalized to an individual's biological profile
Latent world model	Disease prediction and treatment planning	Better prediction of disease progression and treatment outcomes
Autoencoder-based models	Remote patient monitoring	Early detection of health deterioration and continuous monitoring

4. Discussion

The findings of this review show that latent artificial intelligence has developed from an experimental machine learning concept into a useful technology with applications in many areas of healthcare. These models learn compact representations from complex clinical data, making it possible to identify important patterns in medical images, electronic health records, physiological signals, and molecular datasets [1,2,3]. As a result, latent AI is now applied to a wide range of clinical and research problems.

The studies included in this review indicate that latent representations improve disease detection and reduce the need for manually designed features. Variational autoencoders and other latent-variable models have shown good performance in medical imaging, especially for abnormality detection, image reconstruction, and synthetic image generation [1,3,4,5]. Recent

developments, including latent diffusion models and latent world models, have further expanded their use in medical image segmentation, disease progression modelling, and digital twin technology [18,21,22].

The literature also highlights the growing role of latent AI in analyzing electronic health records. By learning patient representations from clinical data collected over time. These models improve the prediction of chronic disease progression, hospital outcomes, and critical illness. They also provide additional information that supports more personalized clinical decision-making [11,12]. Studies on chronic kidney disease and sepsis have shown that combining latent representations with explainable AI improves prediction while making the results easier for clinicians to understand [6,7].

Drug discovery is another area where latent AI has shown significant potential. Continuous latent molecular representations have improved computational drug design by making it easier to search for chemical space and optimize molecular properties [25]. Newer latent-space generative models like transformer-based and energy-based methods, have further improved molecular design. These models also support precision medicine through the integration of multi-omics data and the development of more personalized treatment strategies [10,26,27,28,29]. The available evidence is encouraging but several challenges must be focused before latent AI becomes part of routine clinical practice. Many published studies mainly report technical performance, while prospective studies that evaluate patient outcomes are still limited. External validation in different healthcare systems is also needed to determine whether these models perform consistently in different clinical settings [15,17].

Another important issue is model interpretability. Latent representations improve prediction accuracy, but the internal features learned by these models are not always easy for clinicians to understand. Making these systems more transparent will increase confidence among healthcare professionals and support their use in everyday clinical practice [32]. Bias and fairness also require continued attention. Many current latent AI models have been developed using data from well-resourced healthcare institutions. Their performance may therefore differ when applied to other hospitals or patient populations. More diverse datasets, routine external validation, and regular fairness assessments will be important before these models are widely adopted [33,34].

Patient privacy continues to be another key consideration. Synthetic datasets produced by latent AI may reduce the need to share identifiable patient information, but latent representations should still be protected to reduce the risk of information leakage. Continued work on privacy-preserving AI methods and strong governance policies will help maintain public trust as these technologies continue to develop [31,32]. Overall, the published evidence suggests that latent AI has strong potential to improve disease detection, clinical decision support, drug discovery, and personalized healthcare. Future studies should give greater attention to large multicenter prospective validation, better model interpretability, stronger privacy and fairness safeguards, and clear international regulatory standards. Progress in these areas will support the safe and responsible use of latent AI in routine healthcare practice [15,32,33,34].

5. Limitations of this Review

This review has several limitations that should be considered when interpreting its findings. It was conducted as a structured narrative review and not as a systematic review. The literature search followed a predefined strategy, a formal risk-of-bias assessment and quantitative meta-analysis were not performed. As a result, some degree of author judgment was involved when selecting studies and interpreting the available evidence. Another limitation is the rapidly changing nature of latent artificial intelligence. Research in this field is expanding quickly, and new models, clinical applications, and validation studies continue to appear. The studies included in this review represent the current state of knowledge up to the search period, but they should not be regarded as a complete summary of every healthcare application of latent AI. New evidence published after the review period may further strengthen or modify some of the conclusions presented here.

The quality of the available evidence also varies. Many published studies originate from computer science, artificial intelligence, and bioinformatics journals, where the primary goal is to develop new algorithms or improve technical performance. Fewer studies have evaluated how these technologies affect patient care in routine clinical practice. Therefore, the current literature provides stronger evidence for computational performance than for real-world clinical benefit. This displays the present stage of research in the field rather than a weakness of the review. As more prospective clinical studies become available, a clearer understanding of the true impact of latent AI on patient outcomes is expected.

Table 2. Benefits and challenges of latent AI in healthcare.

Area	Patient benefits	Main challenge
Diagnostic imaging	Earlier and more accurate detection of disease; larger training datasets created using privacy-protecting synthetic images	More studies in different hospitals are needed to confirm clinical benefits
Predictive analytics (EHR, ICU)	Better prediction of disease risk and patient outcomes; fairer prediction of sepsis	Models may learn bias from patient data and perform differently across populations
Drug discovery and precision medicine	Faster discovery of new drug candidates; treatments can be better matched to individual patients using multi-omics data	New drug candidates still require laboratory testing and clear regulatory approval
Remote monitoring and digital twins	Continuous monitoring of patients; earlier detection of health deterioration	Digital twin models are difficult to interpret and still need more clinical validation
Across all clinical applications	Reduced clinician workload and better support for clinical decision-making	AI models need to be more transparent, and regulations are still developing

6. Conclusion

Latent artificial intelligence (AI) has become an important area of healthcare research and is steadily moving toward clinical

practice. Technologies such as variational autoencoders, generative adversarial networks, latent diffusion models, and latent world models have shown their value across a wide range of applications. The studies reviewed in this article indicate that these models can improve disease detection from medical images, provide more accurate risk prediction using electronic health records and physiological data, support the discovery of new drug candidates, and enable continuous patient monitoring. A common strength in all these applications is the ability of latent AI to learn meaningful patterns from complex clinical data that are often difficult to identify using conventional analytical methods. At the same time, the available evidence shows that routine clinical use is still developing. Most published studies have demonstrated strong technical performance, but only few have confirmed clear improvements in patient outcomes through large prospective clinical studies. Other important challenges are also present like improving model interpretability, reducing bias caused by non-representative datasets, protecting patient privacy, and establishing consistent regulatory standards for the safe use of AI in healthcare. Resolving these issues needs a close collaboration between clinicians, AI researchers, biomedical scientists, healthcare organizations, ethicists, and regulatory agencies.

The current evidence suggests that latent AI has great potential to support future healthcare, but its long-term impact will depend on more than advances in algorithms alone. Reliable clinical validation, transparent decision-making, fair performance across diverse patient populations, and responsible governance will be equally important. As these areas continue to improve, latent AI has the potential to become a valuable tool that supports clinicians, strengthens personalized care, and contributes to better health outcomes without replacing the central role of clinical expertise.

Conflict of Interests

The authors declare no conflict of interest

Funding

This study received no specific funding from public, commercial, or not for profit funding agencies.

Ai Tool Declaration

The authors declare that no AI and related tools are used to write the scientific content of this manuscript.

Data Availability

Data will be available on request

References

[1] Zhao Z, Huang H. Trends and applications of variational autoencoders in medical imaging analysis. Comput Med Imaging Graph. 2025. Available from: ScienceDirect.

[2] Bengesi S, El-Sayed H, Sarker MK, Houkpati Y, Irungu J, Oladunni T. Advancements in generative AI: a comprehensive review of GANs, GPT, autoencoders, diffusion models, and transformers. IEEE Access. 2024; 12:69812-37.

[3] Ehrhardt J, Wilms M. Autoencoders and variational autoencoders in medical image analysis. In: Biomedical Image Synthesis and Simulation. Amsterdam: Elsevier; 2022.

[4] Kawata Y, et al. Generative artificial intelligence in medical imaging: foundations, progress, and clinical translation. arXiv. 2025 Aug. Available from: https://arxiv.org/abs/2508.09177.

[5] Di Folco M, Bercea CI, Schnabel JA. Attribute regularized soft introspective variational autoencoder for interpretable cardiac disease classification. arXiv. 2023 https://arxiv.org/abs/2312.08915.

[6] Jawad KMT, Verma A, Amsaad F, Ashraf L. A study on the application of explainable AI on ensemble models for predictive analysis of chronic kidney disease. IEEE Access. 2025; 13:23312-23330. doi:10.1109/ACCESS.2025.3535692.

[7] Chang CH, Wang X, Yang CC. Explainable ai for fair sepsis mortality predictive model. In International Conference on Artificial Intelligence in Medicine 2024 Jul 9 pp. 267-276. Cham: Springer Nature Switzerland.

[8] Bodun DS, Abolade RO, Nwadinigwe CF, Bashiru M, Adegbaju MM, Owolade AJJ, et al. Design and discovery of new HIV-1 RT inhibitors using generative AI, virtual screening, and molecular dynamics simulations. ChemistrySelect. 2025;10(48): e202504102. doi:10.1002/slct.202504102.

[9] Wornow M, Jin D, Anuyah O. Foundation models and generative AI in clinical trials and care: a review of recent advances. 2024-2025.

[10] Alsaedi S, Ogasawara M, Alarawi M, Gao X, Gojobori T. Generative AI approaches genomic and multi-omics analysis. NAR Genom Bioinform. 2025;7: lqaf038.

[11] Wang H, et al. A survey of deep learning-based predictive models using electronic health records. arXiv. 2025. https://arxiv.org/abs/2503.05768.

[12] Munirathnam R, Kanchetti D. Artificial intelligence (AI)-powered predictive models in chronic disease management: a data-driven approach. Int J Comput Sci Inf Technol Res. 2024;5(1):42-54.

[13] Gomez-Cabello CA, Borna S, Pressman S, Haider SA, Haider CR, Forte AJ. Artificial intelligence-based clinical decision support systems in primary care: a scoping review of current clinical implementations. Eur J Investig Health Psychol Educ. 2024;14(3):685-698. doi:10.3390/ejihpe14030045.

[14] Lee SA, Halperin H, Halperin Y, Brokowski T, Chiang JN. Using foundation models to prescribe patients proper antibiotics. In: Wu J, Zhu J, Xu M, Jin Y, editors. Proceedings of the First AAAI Bridge Program on AI for Medicine and Healthcare. Proceedings of Machine Learning Research. 2025; 281:121-132. https://proceedings.mlr.press/v281/lee25a.html.

[15] Awasthi R, Ramachandran SP, Mishra S, Mahapatra D, Arshad H, Atreja A, et al. Artificial intelligence in healthcare: 2024 year in review. medRxiv. 2025 Feb. https://www.medrxiv.org/content/10.1101/2025.02.26.25322978.

[16] Wójcik Z, Dimitrova V, Warrington L, Velikova G, Absolom K. Using artificial intelligence to predict patient outcomes from patient-reported outcome measures: a scoping review. Health Qual Life Outcomes. 2025; 23:37. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11987430/.

[17] Shah SS. The impact of artificial intelligence on health outcomes: a review. Premier Sci J. 2024. Available from: https://premierscience.com/pjs-24-281/.

[18] Qazi MA, Nadeem M, Yaqub M. Beyond generative AI: world models for clinical prediction, counterfactuals, and planning. NeurIPS 2025 Workshop. arXiv. 2025 Nov. Available from: https://arxiv.org/abs/2511.16333.

[19] He R, Takeuchi I. Statistical testing on generative AI anomaly detection tools in Alzheimer's disease diagnosis. arXiv. 2024 Oct. Available from: https://arxiv.org/abs/ 2410.13363.

[20] Kingma DP, Welling M. Auto-encoding variational Bayes. arXiv. 2013. Available from: https://arxiv.org/abs/1312.6114.

[21] Huynh TN, Toan NH, Ba LS, Long TQ. Diffusion model in latent space for medical image segmentation task (MedSegLatDiff). arXiv. 2025 Dec. Available from: https://arxiv.org/abs/2512.01292.

[22] Caetano F, Abdi L, Viviers C, Valiuddin A, van der Sommen F. Med Symm Flow: bridging generative modeling and classification in medical imaging through symmetrical flow matching. arXiv. 2025 Jul. Available from: https://arxiv.org/abs/2507.19098.

[23] Das U. Transforming precision medicine through generative AI: advanced architectures and tailored therapeutic design for patient-specific drug discovery. Chemistry Select. 2025;10(36): e02448. doi:10.1002/slct. 202502448.

[24] Polishchuk PG, Madzhidov TI, Varnek A. Estimation of the size of drug-like chemical space based on GDB-17 data. J Comput Aided Mol Des. 2013;27(8):675-9.

[25] Gómez-Bombarelli R, Wei JN, Duvenaud D, Hernández-Lobato JM, Sánchez-Lengeling B, Sheberla D, et al. Automatic chemical design using a data-driven continuous representation of molecules. ACS Cent Sci. 2018; 4(2):268-76.

[26] Kong D, Huang Y, Xie J, Wu YN. Molecule design by latent prompt transformer. arXiv. 2023 Oct. Available from: https://arxiv.org/abs/2310.03253.

[27] Kong D, Pang B, Han T, Wu YN. Molecule design by latent space energy-based modeling and gradual distribution shifting. arXiv. 2023 Jun. Available from: https://arxiv.org/abs/2306.14902.

[28] Das U. Generative AI for drug discovery and protein design: the next frontier in AI-driven molecular science. Med Drug Discov. 2025; 27:100213. https://www.sciencedirect.com/science/article/pii/S2590098625000107.

[29] Kang SI, Shin JH, Wu BM, Choi HS. Deep generative AI for multi-target therapeutic design: toward self-improving drug discovery framework. Int J Mol Sci. 2025;26(23):11443. https://pmc.ncbi.nlm.nih.gov/articles/PMC12691712/.

[30] Khater T, Alkhatib SA, AlShehhi A, Pitsalidis C, Pappa AM, Ngo ST, Chan V, Truong VK. Generative artificial intelligence-based models' optimization towards molecule design enhancement. J Cheminform. 2025;17(1):116. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12323263/.

[31] Radanliev P. Privacy, ethics, transparency, and accountability in AI systems for wearable devices. Front Digit Health. 2025; 7:1431246. Available from: https://www.frontiersin.org/journals/digital-health/articles/10.3389/fdgth.2025.1431246/full.

[32] Bailo P, Nittari G, Pesel G, Basello E, Spasari T, Ricci G. Governing healthcare AI in the real world: how fairness, transparency, and human oversight can coexist: a narrative review. Sci. 2026;8(2):36.

[33] Hanna M, Pantanowitz L, Jackson B, et al. Ethical and bias considerations in artificial intelligence/machine learning. Mod Pathol. 2024;38:100686. Available from: https://doi.org/10.1016/j.modpat.2024.100686.

[34] Abu-Mahfouz N. Bias in medical AI: algorithmic fairness and ethics challenges. *J Young Investig*. 2026 Jan; 29(1). https://api.semanticscholar.org/CorpusID:285246833